Clinical trials: Dry Eyes
Dry Eye Syndrome
A Dose Ranging Study to Evaluate Safety and Efficacy of Bromfenac Ophthalmic Solution in Dry Eye Disease
A dose ranging study to evaluate safety and efficacy of bromfenac ophthalmic solution in dry eye disease.
- Trial name
- NCT01212471
- Testing
- Bromfenac Ophthalmic Solution A, Bromfenac Ophthalmic Solution B
- Where
- United States
- Volunteers
- 840 people
- Sponsor
- Bausch & Lomb Incorporated
Dry Eye Disease
Clinical Pharmacological Study of AL-43546 Ophthalmic Product in Subjects With Shortened Tear Film Break Up Time
The purpose of the study is to observe lacrimal fluid condition (tear film break-up time) chronologically after a single dose of AL-43546 ophthalmic products（0.15%, 0.25% and vehicle）and 0.1% sodium hyaluronate ophthalmic…
- Trial name
- NCT00760045
- Testing
- Hydroxypropyl Guar Galactomannan, 0.1% sodium hyaluronate ophthalmic solution
- Where
- Japan
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Alcon Research
Dry Age-related Macular Degeneration, Geographic Atrophy
First in Human Study to Evaluate the Safety and Tolerability of GEM103 in Geographic Atrophy Secondary to Dry Age Related Macular Degeneration
The study is designed to identify the maximum tolerated dose (MTD) for intravitreal (IVT) administration of GEM103 in subjects with geographic atrophy (GA) secondary to dry AMD.
- Conditions
- Dry Age-related Macular Degeneration, Geographic Atrophy, Macular Degeneration, Retinal Disease
- Trial name
- NCT04246866
- Testing
- GEM103
- Where
- 12 sites in United States
- Volunteers
- 12 people
- Sponsor
- Gemini Therapeutics, Inc.
Dry Eye Disease Associated to Asthenopia and Accommodative Effort in Video Display Terminal Users
Evaluation of Performance and Safety of Eye Drops With Hydroxypropyl-methylcellulose and Inositol in Drye Eye Disease
This is a profit, multicentric, prospective, single-arm, open-label, non-pharmacological clinical investigation. Patients with diagnosis of moderate to severe dry eye disease with asthenopia and accommodative effort will receive…
- Trial name
- NCT06190054
- Testing
- MERAMIRT
- Where
- 4 sites in Italy
- Volunteers
- 100 people
- Sponsor
- Fidia Farmaceutici s.p.a.
Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome
Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases
This is an investigator initiated trial to assess the efficacy and safety of BRL-301 in the relapse or refractory autoimmune diseases of China.
- Conditions
- Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome, Systemic Sclerosis, Inflammatory Myopathy
- Trial name
- NCT05859997
- Testing
- BRL-301
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Bioray Laboratories
Dry Eye
The Chronology of Lifitegrast Effect on Anterior Surface Rehabilitation (CLEAR) Study
In patients with dry eye, defined as corneal staining and a reduced tear breakup time, lifitegrast will improve higher order aberrations, ocular scatter index, corneal staining, and TBUT as soon as 1 week after initiating…
- Trial name
- CLEAR (NCT04669561)
- Testing
- Lifitegrast 5% Ophthalmic Solution
- Where
- 3 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Research Insight LLC
Dry Eye, Contact Lens Acute Red Eye
Performance and Tolerability of the Medical Device LACRIACT
The goal of this study is testing LACRIACT® eye drops, a medical device, to see how well it works and if people can use it safely.
- Conditions
- Dry Eye, Contact Lens Acute Red Eye, Photophobia, Discomfort
- Trial name
- NCT06159569
- Testing
- LACRIACT
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Laboratórios Baldacci S.A
Dry Eye
A Study of AL-38583 Ophthalmic Solution 0.05%, 0.010% Versus AL-38583 Vehicle for Dry Eye
The purpose of this study is to determine whether AL-38583 ophthalmic solution is effective for treatment of signs and symptoms of dry eye.
- Trial name
- NCT00893139
- Testing
- AL-38583 ophthalmic solution 0.05%, AL-38583 ophthalmic solution 0.10%, AL-38583 vehicle
- Volunteers
- 765 people
- Sponsor
- Alcon Research
Dry Eye Disease
Idroflog® for Treatment of Dry Eye Disease (IDROFLOG)
This study aims at demonstrating the non-inferiority of Idroflog compared to sodium hyaluronate 0.18% for the disease improvement of people with documented history of dry eyes and use of tear substitutes for at least 3 months.
- Trial name
- IDROFLOG (NCT05724056)
- Testing
- Idroflog®, Sodium Hyaluronate 0.18% (Vismed®)
- Where
- 5 sites in France
- Volunteers
- 130 people
- Sponsor
- Alfa Intes Industria Terapeutica Splendore s.r.l.
Dry Eye
Efficacy of Optive Versus Systane Concomitant With Restasis (Cyclosporine A) for the Treatment of Dry Eye Symptoms
The purpose of this study is to evaluate the efficacy of Optive versus Systane used concomitantly with topical cyclosporine for the treatment of dry eye.
- Trial name
- NCT00399061
- Testing
- Systane, Optive, Restasis
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Innovative Medical
Dry Eye Disease
Evaluation of Tears Naturale® Free and Tears Naturale® II Lubricant Eye Drops
The purpose of this post-market clinical follow-up (PMCF) study is to describe the effectiveness and safety of Tears Naturale® Free and Tears Naturale® II lubricant eye drops in subjects experiencing dry eye (DE) symptoms.
- Trial name
- NCT07540884
- Testing
- Tears Naturale Free lubricating eye drops, Tears Naturale II lubricating eye drops
- Where
- 6 sites in Canada
- Volunteers
- 132 people
- Sponsor
- Alcon Research
Allergic Conjunctivitis, Dry Eye
PMCF Study to Evaluate Performance and Safety of "Optrex Double Action Soothing and Lubricating Drops"
Allergic conjunctivitis (or ocular allergy) and dry eye disease (DED) are two major ocular surface disorders affecting millions of people.
- Conditions
- Allergic Conjunctivitis, Dry Eye, Dry Eye Disease
- Trial name
- NCT05824000
- Testing
- Eye drops for itchy and water eyes
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- C.O.C. Farmaceutici S.r.l.
Dry Eye Syndromes
Dose-response Study of OPC-12759 Ophthalmic Suspension
The purpose of this study is to evaluate the dose-response of OPC-12759 ophthalmic suspension in dry eye patients.
- Trial name
- NCT00234078
- Testing
- 0.5% OPC-12759, 1% OPC-12759, 2% OPC-12759
- Where
- Japan
- Volunteers
- 290 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Geographic Atrophy, Dry Age-Related Macular Degeneration
Zimura in Participants With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
The objectives of this study were to evaluate the safety and efficacy of Zimura intravitreal (IVT) administration when administered in participants with geographic atrophy (GA) secondary to dry age-related macular degeneration…
- Trial name
- NCT02686658
- Testing
- Avacincaptad Pegol
- Where
- 78 sites in United States, Croatia and 5 more
- Volunteers
- 286 people
- Sponsor
- IVERIC bio, Inc.
Dry Eye Syndromes
Clinical Investigation to Assess the Efficacy and the Safety of VisuXL® Gel Administered in Patients Affected by Moderate DED
This is a post-market, european multicenter study. This is a randomized, cross-over, double blind study with competitive enrolment, aimed to enroll a total of 90 patients with a diagnosis of moderate dry eye disease (DED).
- Trial name
- NCT04485533
- Testing
- VisuXL® Gel, HYLO®
- Where
- 3 sites in France, Italy and 1 more
- Volunteers
- 90 people
- Sponsor
- VISUfarma SpA
Dry Eye Syndrome
Study to Assess the Safety and Efficacy of BOL-303242-X Ophthalmic Suspension in Dry Eye Syndrome
The objective of this study is to identify the concentration and daily dosing frequency of BOL-303242-X ophthalmic suspension in treating dry eye syndrome over a 12 week dosing period.
- Trial name
- NCT01163643
- Testing
- 0.3% BOL-303242-X ophthalmic suspension, 2% BOL-303242-X ophthalmic suspension, 1% BOL-303242-X ophthalmic suspension
- Where
- United States
- Volunteers
- 356 people
- Sponsor
- Bausch & Lomb Incorporated
Refractory Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myopathies (IIMs)
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
A Basket Trial of Refractory Rheumatoid Arthritis (RA), Sjögren's Disease (SjD), Idiopathic Inflammatory Myopathies (IIMs) and Systemic Sclerosis (SSc) subjects to evaluate the safety and efficacy of AlloNK, a non-genetically…
- Conditions
- Refractory Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myopathies (IIMs), Systemic Sclerosis (SSc), Rheumatoid Arthritis (RA
- Trial name
- NCT06991114
- Testing
- Allogeneic NK Cells
- Where
- 52 sites in United States, Brazil and 9 more
- Volunteers
- 90 people
- Sponsor
- Artiva Biotherapeutics, Inc.
Dry Eye, Dry Eye Disease
PMCF Study to Evaluate Performance and Safety of "HPMC-based Eyedrops" Used to Relieve Dry Eye Symptoms
Dry eye disease (DED), also called keratoconjunctivitis sicca, is a common ocular condition characterized by a loss of homeostasis of the tear film and inflammation of the ocular surface.
- Conditions
- Dry Eye, Dry Eye Disease, Kerato Conjunctivitis Sicca
- Trial name
- NCT05825599
- Testing
- Hydroxypropyl methylcellulose eye drops
- Where
- Italy
- Volunteers
- 80 people
- Sponsor
- C.O.C. Farmaceutici S.r.l.
Dry Eye Disease (DED)
A Non-interventional Study to Evaluate the Anti-inflammatory Effects and the Clinical Efficacy of Topical Water Free Cyclosporin 0.1% Eye Drops in Patients With Dry Eye Disease and Associated Ocular Surface Inflammation Non-responding to Artificial Tears: the FOCUS Study
The FOCUS study aims to evaluate the clinical efficacy of 0.1% cyclosporine eye drops solution (Vevizye®, Laboratoires THEA) in patients with moderate to severe dry eye disease characterized by ocular surface inflammation.
- Trial name
- NCT07234318
- Testing
- Cyclosporin
- Where
- Austria
- Volunteers
- 25 people
- Sponsor
- Laboratoires Thea
Dry Eye, Cataract Surgery
Efficacy Evaluation of SYSTANE® ULTRA in Patients Scheduled for Cataract Surgery
The purpose of this study is to evaluate the effectiveness of FID 112903 (SYSTANE ULTRA® Lubricating Drops) plus standard of care to standard of care alone, in subjects with a history of intermittent eye irritation or dryness…
- Trial name
- NCT01199510
- Testing
- FID 112903 (SYSTANE® ULTRA Lubricant Eye Drops) plus standard of care, Standard of Care
- Volunteers
- 40 people
- Sponsor
- Alcon Research